Ent Instructions for Authors
Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ. Ent Instructions for Authors. Ear, Nose & Throat Journal 2017, 96: 271-272. PMID: 28719713, PMCID: PMC7549076, DOI: 10.1177/014556131709600703.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overChemoradiotherapy, AdjuvantChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLogistic ModelsLymph NodesMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalPrognosisRadiotherapy, AdjuvantRetrospective StudiesSkin NeoplasmsConceptsNonmelanoma skin cancerProgression-free survivalConcurrent chemoradiationLymph nodesLocoregional controlOverall survivalSkin cancerLocalized skin cancerLymph node measurementLymph node positiveGrade 4 thrombocytopeniaPositive lymph nodesSingle tertiary centerKaplan-Meier methodAggressive clinical courseAdjuvant concurrent chemoradiationAdvanced nonmelanoma skin cancersChi-square testAdjuvant radiationAdjuvant therapyClinical courseLocal recurrenceNode positiveTertiary centerCRT patientsPhase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).
Tawfik B, Gerber D, Burtness B, Hughes R, Myers L, Sumer B, Truelson J, Strom T, Kurian P, Saleem S, Pearson J, Zhu H, Khan S. Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC). Journal Of Clinical Oncology 2017, 35: tps6098-tps6098. DOI: 10.1200/jco.2017.35.15_suppl.tps6098.Peer-Reviewed Original ResearchAnaplastic thyroid cancerThyroid cancerCell cycle progressionII trialCycle progressionResponse ratePhase I/II trialOpen-label trialRare thyroid cancerPhase II trialAggressive clinical courseCDK 4/6 inhibitorsEffective treatment optionOverall response rateMTOR inhibitor everolimusATC cell linesRapid cell cycle progressionMedian OSATC patientsPrimary endpointSecondary endpointsMetastatic diseaseTrue response rateAdditional patientsClinical course